| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 09.04.2021 og
angivet som gældende fra 08.04.2021 (1117
dage). |
Ingen historik.
| Branche | | Virksomhedsrådgivning og anden rådgivning om driftsledelse (702200). |
| Sidst opdateret den 17.06.2021 og
angivet som gældende fra 16.06.2021 (1048
dage). |
| Historik | Start | Stop |
|---|
| Virksomhedsrådgivning og anden rådgivning om driftsledelse (702200) | 16.06.2021 | |
| Ikke-finansielle holdingselskaber (642020) | 08.04.2021 | 15.06.2021 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 09.04.2021 og
angivet som gældende fra 08.04.2021 (1117
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | Drug Development Consulting BidCo ApS. |
| Sidst opdateret den 09.04.2021 og
angivet som gældende fra 08.04.2021 (1117
dage). |
Ingen historik.
| Tegningsregel | | Selskabet tegnes af to bestyrelsesmedlemmer i forening. |
| Sidst opdateret den 17.05.2021 og
angivet som gældende fra 17.05.2021 (1078
dage). |
| Fortolkning
(1 tegningsmulighed)
| | 2 bestyrelsesmedlemmer + |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af to bestyrelsesmedlemmer i forening | 17.05.2021 | |
| Selskabet tegnes af direktøren | 08.04.2021 | 16.05.2021 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse C, mellemstor virksomhed
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the financial statements of Drug Development Consulting BidCo ApS for the financial year 1 January – 31 December 2022, which comprise income statement, balance sheet, statement of changes in equity, and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January – 31 December 2022 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the Management's reviewManagement is responsible for the Management's review. Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.
| Bibranche | | Ikke-finansielle holdingselskaber. |
| Sidst opdateret den 17.06.2021
og
angivet som gældende fra 16.06.2021 (1048
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration